2020
Androgenicity and fertility treatment in women with unexplained infertility
Wang ET, Diamond MP, Alvero R, Casson P, Christman GM, Coutifaris C, Hansen KR, Sun F, Legro RS, Robinson RD, Usadi RS, Pisarska MD, Santoro NF, Zhang H, Network I. Androgenicity and fertility treatment in women with unexplained infertility. Fertility And Sterility 2020, 113: 636-641. PMID: 32192596, PMCID: PMC7088440, DOI: 10.1016/j.fertnstert.2019.10.034.Peer-Reviewed Original ResearchConceptsLive birth rateBody mass indexUnexplained infertilityClinical pregnancyMass indexPregnancy lossClinical markersLive birthsAndrogenic activityFree androgen index valuesHigher body mass indexMultivariable logistic regression modelMultiple Intrauterine GestationsNormal uterine cavityHigh waist circumferenceOvarian stimulation treatmentPatent fallopian tubesBirth rateLogistic regression modelsAndrogen markersSerum TTOvarian stimulationRegular mensesInfertility populationIntrauterine gestation
2019
Cervicovaginal fluid proteomic analysis to identify potential biomarkers for preterm birth
Parry S, Leite R, Esplin MS, Bukowski R, Zhang H, Varner M, Andrews WW, Saade GR, Ilekis J, Reddy UM, Huang H, Sadovsky Y, Blair IA, Biggio J, Research E. Cervicovaginal fluid proteomic analysis to identify potential biomarkers for preterm birth. American Journal Of Obstetrics And Gynecology 2019, 222: 493.e1-493.e13. PMID: 31758918, PMCID: PMC7196033, DOI: 10.1016/j.ajog.2019.11.1252.Peer-Reviewed Original ResearchConceptsPreterm birth casesSpontaneous preterm birthCervicovaginal fluid samplesEnzyme-linked immunosorbentTerm delivery controlsPreterm birthStudy visitBirth casesFluid samplesPotential biomarkersSpontaneous preterm birth ratePrior spontaneous preterm birthEarly spontaneous preterm birthCervical length screeningThird study visitVaginal mucosal cellsPreterm birth rateHigh-risk cohortCase-control studyReliable screening testAvailable biological fluidIndependent study groupsNeonatal morbidityObstetrical historyAsymptomatic womenAssociations Between Anti-Mullerian Hormone and Cardiometabolic Health in Reproductive Age Women Are Explained by Body Mass Index
Rios JS, Greenwood EA, Pavone MEG, Cedars MI, Legro RS, Diamond MP, Santoro N, Sun F, Robinson RD, Christman G, Zhang H, Huddleston HG. Associations Between Anti-Mullerian Hormone and Cardiometabolic Health in Reproductive Age Women Are Explained by Body Mass Index. The Journal Of Clinical Endocrinology & Metabolism 2019, 105: dgz012. PMID: 31586179, PMCID: PMC7024739, DOI: 10.1210/clinem/dgz012.Peer-Reviewed Original ResearchConceptsHomeostasis model assessment-insulin resistancePolycystic ovary syndromeAnti-Mullerian hormoneBody mass indexC-reactive proteinUnexplained infertilityWaist circumferenceOVA groupLipoprotein cholesterolMass indexRelationship of AMHModel assessment-insulin resistanceHigh-density lipoprotein cholesterolLow-density lipoprotein cholesterolSite-adjusted modelsAssessment-insulin resistanceAntral follicle countCardio-metabolic healthReproductive-aged womenMultivariable linear regression modelsReproductive-age womenClinical populationsLow-density lipoproteinCardiometabolic agingCardiometabolic indicesAssociation between testosterone, semen parameters, and live birth in men with unexplained infertility in an intrauterine insemination population
Trussell JC, Coward RM, Santoro N, Stetter C, Kunselman A, Diamond MP, Hansen KR, Krawetz SA, Legro RS, Heisenleder D, Smith J, Steiner A, Wild R, Casson P, Coutifaris C, Alvero RR, Robinson RB, Christman G, Patrizio P, Zhang H, Lindgren MC, Network R. Association between testosterone, semen parameters, and live birth in men with unexplained infertility in an intrauterine insemination population. Fertility And Sterility 2019, 111: 1129-1134. PMID: 30982604, PMCID: PMC6557574, DOI: 10.1016/j.fertnstert.2019.01.034.Peer-Reviewed Original ResearchMeSH KeywordsAdultBiomarkersDown-RegulationFemaleFertilityHumansInfertility, MaleInsemination, Artificial, HomologousLive BirthMaleMulticenter Studies as TopicPregnancyPregnancy RateRandomized Controlled Trials as TopicRisk FactorsSperm CountSperm MotilitySpermatogenesisTestosteroneTreatment OutcomeConceptsUnexplained infertilityLow TTMale partnersLive birthsSemen parametersSecondary analysisMultiple Intrauterine GestationsLive birth rateBody mass indexMulticenter clinical trialAbnormal sperm morphologyOvarian stimulationIntrauterine gestationPregnancy outcomesMass indexInfertility clinicClinical trialsMAIN OUTCOMETotal motile spermSemen analysisAbnormal spermatogenesisInfertilityLogistic regressionSperm concentrationSemen volume
2018
Midluteal Progesterone: A Marker of Treatment Outcomes in Couples With Unexplained Infertility
Hansen KR, Eisenberg E, Baker V, Hill MJ, Chen S, Talken S, Diamond MP, Legro RS, Coutifaris C, Alvero R, Robinson RD, Casson P, Christman GM, Santoro N, Zhang H, Wild RA, Network N. Midluteal Progesterone: A Marker of Treatment Outcomes in Couples With Unexplained Infertility. The Journal Of Clinical Endocrinology & Metabolism 2018, 103: 2743-2751. PMID: 29767754, PMCID: PMC6276712, DOI: 10.1210/jc.2018-00642.Peer-Reviewed Original ResearchConceptsMidluteal progesterone levelsUnexplained infertilityLive birthsOS-IUIProgesterone levelsPregnancy outcomesClinical trialsTreatment groupsIntrauterine insemination treatmentMultiple Intrauterine GestationsOvarian stimulation medicationSuccessful pregnancy outcomeMulticenter clinical trialLow progesterone levelsMidluteal progesteroneClomiphene citrateOvarian stimulationIntrauterine gestationEndometrial changesPathophysiologic mechanismsGonadotropin treatmentStimulation medicationsProgesterone exposureTreatment outcomesProgesterone concentrationsEvaluation, validation and refinement of noninvasive diagnostic biomarkers for endometriosis (ENDOmarker): A protocol to phenotype bio-specimens for discovery and validation
Barnhart K, Giudice L, Young S, Thomas T, Diamond MP, Segars J, Youssef WA, Krawetz S, Santoro N, Eisenberg E, Zhang H, Network F. Evaluation, validation and refinement of noninvasive diagnostic biomarkers for endometriosis (ENDOmarker): A protocol to phenotype bio-specimens for discovery and validation. Contemporary Clinical Trials 2018, 68: 1-6. PMID: 29524590, PMCID: PMC5899676, DOI: 10.1016/j.cct.2018.03.002.Peer-Reviewed Original ResearchConceptsReproductive Medicine NetworkDisease-specific questionnaireReproductive-aged womenTime of surgeryEstrogen-dependent conditionStage of endometriosisExtensive clinical evaluationSeverity of diseaseNoninvasive diagnostic biomarkersAcademic medical centerPelvic painEndometrial biopsyNonsurgical diagnosisSerum cytokinesSurgical ablationGynecologic surgeryClinical evaluationClinical reasonsMedical CenterAged womenPharmacological controlEndometriosisGenomic classifierSpecific questionnaireTherapy shifts
2016
A method for integrating neuroimaging into genetic models of learning performance
Mehta CM, Gruen JR, Zhang H. A method for integrating neuroimaging into genetic models of learning performance. Genetic Epidemiology 2016, 41: 4-17. PMID: 27859682, PMCID: PMC5154929, DOI: 10.1002/gepi.22025.Peer-Reviewed Original ResearchTesting Violations of the Exponential Assumption in Cancer Clinical Trials with Survival Endpoints
Han G, Schell MJ, Zhang H, Zelterman D, Pusztai L, Adelson K, Hatzis C. Testing Violations of the Exponential Assumption in Cancer Clinical Trials with Survival Endpoints. Biometrics 2016, 73: 687-695. PMID: 27669414, PMCID: PMC6093291, DOI: 10.1111/biom.12590.Peer-Reviewed Original ResearchBaseline AMH Level Associated With Ovulation Following Ovulation Induction in Women With Polycystic Ovary Syndrome
Mumford SL, Legro RS, Diamond MP, Coutifaris C, Steiner AZ, Schlaff WD, Alvero R, Christman GM, Casson PR, Huang H, Santoro N, Eisenberg E, Zhang H, Cedars MI. Baseline AMH Level Associated With Ovulation Following Ovulation Induction in Women With Polycystic Ovary Syndrome. The Journal Of Clinical Endocrinology & Metabolism 2016, 101: 3288-3296. PMID: 27228369, PMCID: PMC5010565, DOI: 10.1210/jc.2016-1340.Peer-Reviewed Original ResearchConceptsPolycystic ovary syndromeAnti-Müllerian hormoneSerum anti-Müllerian hormoneAMH levelsOvulation inductionOvary syndromeHigh serum anti-Müllerian hormoneMean AMHSensitivity of folliclesHigher AMH levelsAntral follicle countBody mass indexRandomized clinical trialsOvulation induction medicationsWomen ages 18II trialFollicle countMass indexInduction medicationsInsulin levelsClinical trialsOvulatory responseHealth centersAromatase activityFSH stimulation
2015
Chlamydia trachomatis immunoglobulin G3 seropositivity is a predictor of reproductive outcomes in infertile women with patent fallopian tubes
Steiner AZ, Diamond MP, Legro RS, Schlaff WD, Barnhart KT, Casson PR, Christman GM, Alvero R, Hansen KR, Geisler WM, Thomas T, Santoro N, Zhang H, Eisenberg E, Network R. Chlamydia trachomatis immunoglobulin G3 seropositivity is a predictor of reproductive outcomes in infertile women with patent fallopian tubes. Fertility And Sterility 2015, 104: 1522-1526. PMID: 26413816, PMCID: PMC4663111, DOI: 10.1016/j.fertnstert.2015.08.022.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntibodies, BacterialBiomarkersChi-Square DistributionChlamydia InfectionsChlamydia trachomatisEnzyme-Linked Immunosorbent AssayFallopian TubesFemaleHumansImmunoglobulin GInfertility, FemaleLinear ModelsLive BirthMultivariate AnalysisOdds RatioPredictive Value of TestsPregnancyPregnancy RatePregnancy, EctopicReproductive Techniques, AssistedRisk AssessmentRisk FactorsSerologic TestsTreatment OutcomeUltrasonographyYoung AdultConceptsEctopic pregnancySeropositive womenInfertile womenTubal patencyLive birthsPolycystic Ovary Syndrome IIChlamydia trachomatis seropositivityMultiple Intrauterine GestationsPatent fallopian tubesEnzyme-linked immunosorbentCurrent alcohol useC. trachomatis elementary bodiesOvarian stimulationCohort studyIntrauterine gestationPregnancy outcomesPrimary outcomeTreatment medicationsPatent tubesSmoking statusOutpatient clinicIgG3 antibodiesFallopian tubeRelative riskMAIN OUTCOMEA Genome‐Wide Association Study of Early Spontaneous Preterm Delivery
Zhang H, Baldwin DA, Bukowski RK, Parry S, Xu Y, Song C, Andrews WW, Saade GR, Esplin MS, Sadovsky Y, Reddy UM, Ilekis J, Varner M, Biggio JR, Research F. A Genome‐Wide Association Study of Early Spontaneous Preterm Delivery. Genetic Epidemiology 2015, 39: 217-226. PMID: 25599974, PMCID: PMC4366311, DOI: 10.1002/gepi.21887.Peer-Reviewed Original ResearchConceptsSpontaneous preterm birthMaternal single nucleotide polymorphismsSPTB casesPreterm birthValidation cohortSingle nucleotide polymorphismsEarly spontaneous preterm deliveryP-valueTerm controlsTerm delivery controlsSpontaneous preterm deliveryMother-infant pairsCase-control studyIndependent validation cohortRace/ethnicityPreterm deliveryInfant morbidityMaternal ageControl groupMultiple testing adjustmentMultiple comparisonsCohortBirthNucleotide polymorphismsGenome-wide association studies
2014
Maternal serum serpin B7 is associated with early spontaneous preterm birth
Parry S, Zhang H, Biggio J, Bukowski R, Varner M, Xu Y, Andrews WW, Saade GR, Esplin MS, Leite R, Ilekis J, Reddy UM, Sadovsky Y, Blair IA, Research E. Maternal serum serpin B7 is associated with early spontaneous preterm birth. American Journal Of Obstetrics And Gynecology 2014, 211: 678.e1-678.e12. PMID: 24954659, PMCID: PMC4254341, DOI: 10.1016/j.ajog.2014.06.035.Peer-Reviewed Original ResearchConceptsSpontaneous preterm birthEarly spontaneous preterm birthPreterm birthMaternal serumSerum samplesPrevious spontaneous preterm birthSubsequent preterm deliveryProtein expressionLower gestational ageGestational age windowsCase-control studyCandidate protein expressionSerum proteomic analysisIndividual serum samplesPooled serum samplesSpontaneous pretermPreterm deliveryWeeks' gestationGestational ageTerm deliveryPregnant womenSerum biomarkersSerum concentrationsFetal membranesClinical sites